文献速递肿瘤 PET/CT

68Ga-PSMA是一种用于肝细胞癌显像的新型PET-CT示踪剂:一项前瞻性先导研究

68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study.
PubMed 文献 · J Nucl Med · 2018-07-12

这项前瞻性先导研究纳入7例肝细胞癌患者的41个肝脏病灶(37个疑似恶性、4个再生结节),比较68Ga-PSMA与18F-FDG PET-CT的摄取并与增强CT血供特征及PSMA免疫组化对照。37个肿瘤病灶中36个68Ga-PSMA摄取增高,仅10个18F-FDG阳性;68Ga-PSMA在强化区摄取显著高于非强化区,而18F-FDG在非强化区更高(均P<0.001)。作者认为68Ga-PSMA PET-CT在肝细胞癌显像上优于18F-FDG PET-CT,是潜在的新型显像手段。

要点

  • 37个肝细胞癌肿瘤病灶中36个68Ga-PSMA摄取增高,18F-FDG仅10个阳性。
  • 4个再生结节对两种示踪剂均无摄取增高。
  • 68Ga-PSMA摄取(TBR SUVmax)与血供(TBR-HU)相关(Spearman r=0.866,P<0.001)。

核心结论

  • 作者结论认为68Ga-PSMA PET-CT在肝细胞癌患者显像上优于18F-FDG PET-CT,是潜在的新型显像手段。
  • 肝细胞癌病灶多为富血供,68Ga-PSMA摄取位于肿瘤微血管。

研究设计与样本

  • 前瞻性先导研究,纳入7例肝细胞癌患者共41个肝脏病灶,其中37个疑似恶性病灶、4个再生结节。
  • 对每个肝脏病灶测量68Ga-PSMA与18F-FDG的SUV及病灶-肝脏本底比值(TBR-SUV),并与增强CT的动态特征(HU及TBR-HU)做相关分析。
  • 对5例肝细胞癌患者肿瘤组织行PSMA免疫组化染色,并与3例前列腺癌对照样本比较。

主要发现

  • 37个肿瘤病灶中36个68Ga-PSMA摄取增高,再生结节均无68Ga-PSMA摄取增高;仅10个病灶18F-FDG阳性。
  • 按强化方式分为27个均匀强化病灶、9个同一病灶内兼有强化与非强化区的「马赛克」强化病灶和1个非强化病灶,后者是唯一无68Ga-PSMA摄取的病灶。
  • Mann-Whitney检验显示68Ga-PSMA摄取在强化肿瘤区显著高于非强化区,而18F-FDG摄取在非强化区更高,两者均P<0.001。
  • 68Ga-PSMA摄取(TBR SUVmax)与血供(TBR-HU)相关(Spearman r=0.866,P<0.001)。
  • 免疫组化显示肝细胞癌瘤内微血管PSMA强染色,前列腺癌样本则呈胞质与胞膜染色、主要位于腔缘;2例患者经68Ga-PSMA PET-CT发现意外的肝外转移。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background:68Ga-Prostate Specific Membrane Antigen (68Ga-PSMA), a positron emission tomography (PET) tracer that was recently introduce for imaging of prostate cancer, may accumulate in other solid tumors including Hepatocellular Carcinoma (HCC). The aim of the study was to assess the potential role of 68Ga-PSMA PET-Computed Tomography (CT) for imaging of HCC. Material and Methods: A prospective pilot study in seven patients with HCC with 41 liver lesions: 37 suspected malignant lesions (tumor lesions) and 4 regenerative nodules. For each liver lesion, uptake of 68Ga-PSMA and 18F-FDG uptake were measured [standard uptake value (SUV) and lesion-to-liver background ratios (TBR-SUV)], and correlated with dynamic characteristics (HU and TBR-HU) obtained on contrast enhanced CT data. Immunohistochemistry staining of PSMA in the tumor tissue was analyzed in samples obtained from 5 patients with HCC and compared to control samples from 3 patients with prostate cancer. Results: Thirty-six of the 37 tumor lesions and none of the regenerative nodules showed increased 68Ga-PSMA uptake while only 10 lesions were 18F-FDG avid. Based on contrast enhancement, tumor lesions were categorized into 27 homogeneously enhancing lesions, nine lesions with "mosaic" enhancement composed of enhancing and non-enhancing regions in the same lesion and a single non-enhancing lesion, the latter being the only non-68Ga-PSMA avid lesion. Using the Mann-Whitney test, 68Ga-PSMA uptake was found significantly higher in enhancing tumor areas compared to non-enhancing areas and in contrast, 18F-FDG uptake was higher in non-enhancing areas, P<0.001 for both. 68Ga-PSMA uptake (TBR SUVmax) was found to correlate with vascularity (TBR-HU) (Spearman r=0.866, p<0.001). Immunohistochemistry showed intense intra-tumoral microvessel staining for PSMA in HCC, in contrast with cytoplasmic and membranous staining, mainly in the luminal border, in prostate cancer samples. In two of the study patients 68Ga-PSMA PET-CT identified unexpected extrahepatic metastases. Four regenerative liver nodules showed no increased uptake of either of the PET tracers. Conclusion:68Ga-PSMA PET-CT is superior to 18F-FDG PET-CT in imaging patients with HCC. HCC lesions are more commonly hypervascular taking up 68Ga-PSMA in tumoral micro-vessels. 68Ga-PSMA PET-CT is a potential novel modality for imaging patients with HCC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kesler M, Levine C, Hershkovitz D, et al. 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study. J Nucl Med. 2018. PMID: 30002112. doi:10.2967/jnumed.118.214833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。